A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

141

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

January 31, 2017

Conditions

Chronic Hepatitis CHepatitis C VirusHCVDirect-Acting Antiviral Agent (DAA)-Experienced

Interventions

DRUG

ABT-493, ABT-530

ABT-493 (tablet) dosed with ABT-530 (tablet)

DRUG

ribavirin (RBV)

Tablet

DRUG

ABT-493/ABT-530

Tablet; ABT-493 coformulated with ABT-530